| __timestamp | Lantheus Holdings, Inc. | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 176081000 | 94103000 |
| Thursday, January 1, 2015 | 157939000 | 146194000 |
| Friday, January 1, 2016 | 164073000 | 130000 |
| Sunday, January 1, 2017 | 169243000 | 7353000 |
| Monday, January 1, 2018 | 168489000 | 34193000 |
| Tuesday, January 1, 2019 | 172526000 | 56586000 |
| Wednesday, January 1, 2020 | 200649000 | 63382000 |
| Friday, January 1, 2021 | 237513000 | 97049000 |
| Saturday, January 1, 2022 | 353358000 | 139989000 |
| Sunday, January 1, 2023 | 586886000 | 150343000 |
Cracking the code
In the ever-evolving landscape of biotechnology, understanding cost structures is crucial. Lantheus Holdings, Inc. and Sarepta Therapeutics, Inc. offer a fascinating study in contrasts. From 2014 to 2023, Lantheus Holdings saw a staggering 233% increase in their cost of revenue, peaking at $587 million in 2023. This growth reflects their expanding operations and market reach. Meanwhile, Sarepta Therapeutics experienced a more modest 60% rise, reaching $150 million in the same year. This difference highlights varying business strategies and market conditions. Notably, Sarepta's cost of revenue was minimal in 2016, indicating a strategic pivot or operational shift. These insights underscore the dynamic nature of the biotech industry, where financial agility and strategic foresight are key to navigating market challenges.
Cost of Revenue: Key Insights for AbbVie Inc. and Sarepta Therapeutics, Inc.
Cost of Revenue Comparison: Sanofi vs Lantheus Holdings, Inc.
Cost of Revenue: Key Insights for Teva Pharmaceutical Industries Limited and Lantheus Holdings, Inc.
Analyzing Cost of Revenue: Viatris Inc. and Lantheus Holdings, Inc.
Analyzing Cost of Revenue: Intra-Cellular Therapies, Inc. and Lantheus Holdings, Inc.
Cost of Revenue Trends: Sarepta Therapeutics, Inc. vs Veracyte, Inc.
Cost of Revenue Trends: Sarepta Therapeutics, Inc. vs Xencor, Inc.
Cost Insights: Breaking Down Sarepta Therapeutics, Inc. and MiMedx Group, Inc.'s Expenses
Cost of Revenue: Key Insights for Lantheus Holdings, Inc. and Corcept Therapeutics Incorporated
Lantheus Holdings, Inc. vs Travere Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Lantheus Holdings, Inc. vs BioCryst Pharmaceuticals, Inc.